Incyte

News

Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.

News

Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.

News

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

News

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

News

NHS patients in England with vitiligo will soon be able to access Incyte's Opzelura, the first drug shown to reverse the skin-lightening disorder.

News

Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer